You are here

New and novel technologies for vaccine delivery

<div>coloured block</div>

Thursday 25th Feb 2016, 05.00pm
Lecture Theatre, Oxford Martin School, 34 Broad Street (corner of Holywell and Catte Streets), Oxford, OX1 3BD

Vaccination has saved more lives than any other medical advancement, but traditional methods of vaccine delivery are fast becoming outdated in our technological age. Dr Christine Rollier, James Martin Fellow on the Oxford Martin Programme on Vaccines will look at new methods of vaccine delivery technology that promise cheaper, safer and pain free implementation. Christine will be joined by Dr Pawan Dulal, a researcher in the Vaccine Delivery Technologies group at the Jenner Institute, who is developing a technology to render vaccines thermo-stable, a process that could revolutionise the global distribution of vaccine technology. 

Join in on Twitter #tomorrowtech

This event will be live streamed on our YouTube channel

About the speaker

Dr Christine Rollier Christine Rollier is a James Martin Fellow on the Oxford Martin Programme on Vaccines, a Jenner Investigator at the Oxford Vaccine Group, and a Post Doctoral Research Associate at the Department of Paediatrics, all at the University of Oxford.

She studied biochemistry and obtained her PhD at the University of Lyon I in 2000, studying DNA immunization as a therapeutic approach against chronic Hepatitis B Virus infection.

She trained in immunology, specialising in vaccine development at Institut National de la Sante et Recherche Medicale (INSERM), Lyon, France. She proceeded to work on novel vaccine development against Hepatitis C Virus chronic infection at the Biomedical Primate Research Center, The Netherlands for five years, before joining the Jenner Institute at the University of Oxford in 2007 as a senior immunologist to work on improvements of vaccine vectors against malaria.

She started her current position at the Oxford Vaccine Group in 2010, and her research activities, funded by the Oxford Biomedical Research Centre, Medical Research Council and charities, include pre-clinical and clinical investigation of new and improved vaccines against bacterial infections such as serogroup B meningococcus.